Zurich Switzerland October 27 2014 Ndash Haselmeier Announces That Biocon One Of Asiarsquos Premier Biotechnology Companies Has Just Launched Insupenreg Ez In India The Insupenreg Ez Is A Second Generation Pen And Follows On The Success S Of Bioconrsquos Premier Insulin Delivery Device Insupenreg Under The Terms Of The Agreement Between The Two Companies Biocon Has Worldwide Distribution Rights To Insupenreg Ez For Use With Bioconrsquos Insulin Basalogtrade And Insugentrade And Insulin Analoguesthe Insupenreg Ez Is A Reusable Insulin Pen Based On Haselmeierrsquos New Ipensup2 Platform And Is Designed To Be Easy To Use And Provide A Smoother Injection Experience It Can Deliver Insulin Doses From 1 Unit 001 Ml To 60 Units 060 Ml In Increments Of 1 Unit 001 Ml With Insulin Preparations Of 100 Iuml And Features An Audible Sound When Dialling A Dose For Accurate And Reliable Dosing The Insupenreg Ez Is Available In An Egg Shell White Thermoresistant Lightweight Terluran Body And Is Available In Different Colours For Differentiating Insulinsthe Launch Of Insupenreg Ez Represents Another Milestone In The Longstanding Relationship Between Biocon And Haselmeier Ldquohaselmeier Is Delighted To Collaborate With Biocon And Contribute To The Market Introduction Of Insupenreg Ezrdquo Says Sandra De Haan Director Project Management At Haselmeier Gmbhabout Haselmeierfounded In Stuttgart In 1920 Haselmeier Is One Of The Leading Designers And Manufacturers Of Injection Systems Haselmeierrsquos Devices Feature Unique Function Design And Technology And Are Marketed By Leading Pharmaceutical And Biotechnology Companies Around The World At Five Locations On Three Continents Haselmeier Develops And Produces Innovative Technology For Drug Delivery Which Enhances The Health And Daily Life Of The Patient Please Find Further Information Under Wwwhaselmeiercomabout Bioconestablished In 1978 Biocon Limited Bse Code 532523 Nse Id Biocon Isin Id Ine376g01013 Is India39s Largest Biotechnology Company By Revenue The Group Promoted By Ms Kiran Mazumdarshaw Is A Fullyintegrated Innovationdriven Healthcare Enterprise With Strategic Focus On Biopharmaceuticals And Research Services Bioconrsquos Value Chain Traverses The Entire Length Of Discovery Development And Commercialization Of Novel Therapeutics With Successful Initiatives In Clinical Development Bioprocessing And Global Marketing Biocon Delivers Products And Solutions To Partners And Customers In Approximately 75 Countries Across The Globe Many Of These Products Have Usfda And Ema Acceptance Bioconrsquos Robust Product Offering Includes The Worldrsquos First Pichiabased Recombinant Human Insulin Insugenreg And Indiarsquos First Indigenously Produced Monoclonal Antibody Biomabegfrtmwwwbioconcom
